Bicycle Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

March 8, 2022 |

1 min read

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 8:00 a.m. ET.

March 8, 2022 12:00 UTC

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE) -- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 32^nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 8:00 a.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycle’s Website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the fireside chat date.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.